Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.51 |
| ▸ | DRD3 | P35462 | 5/20 | 0.51 |
| ▸ | CCR2 | P41597 | 5/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6811480 | 1.00 | DRD2 (0.51) | DRD2DRD3CCR2ADRA1ADRD4 | |
| SCHEMBL6710630 | 0.92 | CCR2 (0.53) | DRD2DRD3CCR2ADRA1ADRD4 | |
| SCHEMBL6808300 | 0.88 | CCR2 (0.48) | DRD2DRD3CCR2ADRA1ADRD4 | |
| SCHEMBL3115330 | 0.83 | DRD3 (0.60) | DRD2DRD3ADRA1ADRD4SLC2A1 | |
| Hydrochloric Acid SCHEMBL6712354 | 0.83 | SLC2A1 (0.59) | DRD2DRD3CCR2DRD4SLC2A1 | |
| SCHEMBL3106225 | 0.82 | SLC2A1 (0.60) | DRD2DRD3CCR2DRD4SLC2A1 | |
| SCHEMBL6719658 | 0.81 | CCR2 (0.56) | DRD2DRD3CCR2ADRA1ADRD4 | |
| Hydrochloric Acid SCHEMBL6707202 | 0.78 | DRD2 (0.53) | DRD2DRD3DRD4SLC2A1 | |
| SCHEMBL3117184 | 0.77 | DRD2 (0.54) | DRD2DRD3DRD4SLC2A1 | |
| SCHEMBL3121723 | 0.77 | DRD2 (0.51) | DRD2DRD3DRD4SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | claimed |
| US-9023656-B2 | Reactive mass labels | ELECTROPHORETICS LIMITED (GB) | 2015-05-05 | — | — | US | disclosed |
| EP-1907860-B1 | MASS LABELS | ELECTROPHORETICS LTD (GB) | 2010-11-17 | — | — | EP | disclosed |
| US-20100178710-A1 | Mass Labels | ELECTROPHORETICS LIMITED (GB) | 2010-07-15 | — | — | US | disclosed |
| CN-101313223-A | Mass labels for biomolecules comprising a 2, 6-dimethyl-piperidin-1-yl-methylene or pyrimidin-2-ylthiomethylene mass label moiety and a succinimidyl-oxy-carbonyl active functional group | ELECTROPHORETICS LTD (GB) | 2008-11-26 | — | — | CN | disclosed |
| EP-1907860-A2 | MASS LABELS | Electrophoretics Limited (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007012849-A2 | MASS LABELS FOR BIOMOLECULES CONTAINING A 2,6-DIMETHYL-PIPERIDIN-l-YL METHYLENE OR A PYRIMIDIN-2-YL THIOMETHYLENE MASS MARKER MOIETY AND A SUCCINIMID-OXY-CARBONYL REACTIVE FUNCTIONAL GROUP | ELECTROPHORETICS LIMITED (GB) | 2007-02-01 | — | — | WO | disclosed |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178710-A1 | Mass Labels | B2M, SRRM2, CCNB1 | DRD2 3923/4885DRD3 2912/4885CCR2 73/4885 |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | LDLR, NR1H2, NCOR1 | DRD2 1008/4885DRD3 1137/4885CCR2 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.